Navigation Links
Reportlinker Adds A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
Date:5/23/2011

NEW YORK, May 23, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

http://www.reportlinker.com/p0507256/A-Decision-Support-Tool-for-Optimizing-The-Lymphoma-Pipeline-From-Research-and-Development-to-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. BioSeeker has applied its unique drug assessment methodology to stratify the lymphoma pipeline and discern the level of competition in fine detail.

Major Findings from this report:

- The identified competitive landscape of lymphoma drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing lymphoma drugs in 36 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lymphoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, TOP2A, ALK and CD19.

- Eight out of ten drug target strategies in Phase III development are new to lymphoma drugs and at the same time the greatest numbers of new target strategies are found in Phase I (33%) and Phase II development (27%).

- Small molecules, antibodies and proteins are the dominating compound strategies of lymphoma drugs, which represent 90% of the entire pipeline. Cell- and gene therapy based lymphoma drugs have the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lymphoma drugs.

- The highest number of described drug target strategies of lymphoma drugs belongs to Bristol-Myers Squibb (9), Hoffmann-La Roche (8), GlaxoSmithKline (8) and Pfizer (8).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Supporting development of integrative molecule, pathway and disease area strategies

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lymphoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3

2 About Cancer Highlights™ 5

2.1 Cancer Focus Areas 5

2.2 Subscribe Today and Start Saving 6

2.2.1 Type of License 6

2.3 Additional Information 6

2.4 BioSeeker Group's Oncology Team 6

3 Methodology 7

3.1 Cancer Highlights Five Pillar Drug Assessment 7

4 Table of Contents 9

4.1 List of Figures 19

4.2 List of Tables 19

5 Introduction 26

5.1 The Scope of this Report 26

5.2 Definitions 29

5.3 Abbreviations 29

6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment 30

6.1 Drug Repositioning in Oncology 30

6.2 Introduction to Targets of Lymphoma Drugs 31

6.2.1 Acid Phosphatase Activity Targets 38

6.2.2 Auxiliary Transport Protein Activity Targets 39

6.2.3 Carboxy-lyase Activity Targets 40

6.2.4 Caspase Activator Activity Targets 41

6.2.5 Catalytic Activity Targets 42

6.2.6 Cell Adhesion Molecule Activity Targets 50

6.2.7 Chaperone Activity Targets 53

6.2.8 Chemokine Activity Targets 56

6.2.9 Cysteine-type Peptidase Activity Targets 58

6.2.10 Cytokine Activity Targets 61

6.2.11 Deaminase Activity Targets 68

6.2.12 DNA Binding Targets 69

6.2.13 DNA Repair Protein Targets 71

6.2.14 DNA Topoisomerase Activity Targets 72

6.2.15 DNA-directed DNA Polymerase Activity Targets 76

6.2.16 DNA-methyltransferase Activity Targets 82

6.2.17 G-protein Coupled Receptor Activity Targets 83

6.2.18 Glutathione Transferase Activity Targets 86

6.2.19 Growth Factor Activity Targets 88

6.2.20 GTPase Activator Activity Targets 91

6.2.21 Hormone Activity Targets 92

6.2.22 Hydrolase Activity Targets 93

6.2.23 Kinase Activity Targets 96

6.2.24 Kinase Binding Targets 107

6.2.25 Kinase Regulator Activity Targets 110

6.2.26 Ligand-dependent Nuclear Receptor Activity Targets 111

6.2.27 Ligase Activity Targets 115

6.2.28 Lipid Kinase Activity Targets 122

6.2.29 Lipid Phosphatase Activity Targets 130

6.2.30 MHC Class I Receptor Activity Targets 131

6.2.31 Molecular Function Unknown Targets 132

6.2.32 Motor Activity Targets 136

6.2.33 Oxidoreductase Activity Targets 138

6.2.34 Phosphorylase Activity Targets 143

6.2.35 Protein Binding Targets 145

6.2.36 Protein Serine/Threonine Kinase Activity Targets 149

6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets 180

6.2.38 Protein-tyrosine Kinase Activity Targets 185

6.2.39 Receptor Activity Targets 196

6.2.40 Receptor Binding Targets 220

6.2.41 Receptor Signaling Complex Scaffold Activity Targets 226

6.2.42 RNA Binding Targets 232

6.2.43 Serine-type Peptidase Activity Targets 233

6.2.44 Structural Constituent of Cytoskeleton Targets 234

6.2.45 Superoxide Dismutase Activity Targets 235

6.2.46 T Cell Receptor Activity Targets 237

6.2.47 Transcription Factor Activity Targets 242

6.2.48 Transcription Regulator Activity Targets 256

6.2.49 Translation Regulator Activity Targets 267

6.2.50 Transmembrane Receptor Activity Targets 271

6.2.51 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 277

6.2.52 Transporter Activity Targets 302

6.2.53 Ubiquitin-specific Protease Activity Targets 309

6.2.54 Other Targets 312

6.3 The Cancer Genome Project and Targets of Lymphoma Drugs 315

6.3.1 Targets of Lymphoma Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 315

6.4 Structure-based Drug Design in Lymphoma Therapeutics is Stimulated by Available Structure Data on Biological Targets 321

6.5 Target-Target Interactions among Identified Targets of Lymphoma Drugs 325

6.6 The Drug-Target Competitive Landscape 330

6.7 Protein Expression Levels of Identified Targets of Lymphoma Drugs 334

6.8 Pathway Assessment of Lymphoma Drugs 338

6.8.1 Tools for Analysis of Cancer Pathways 339

6.8.2 Pathway Assessment 340

7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development 388

7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Lymphoma Drugs 392

7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 394

7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 396

7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 400

7.5 Preclinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs 405

7.6 Drug Target Strategies of Suspended or Terminated Lymphoma Drugs 408

7.7 Target Strategy Development Profiles of Lymphoma Drugs 410

7.7.1 Marketed 414

7.7.2 Phase III 430

7.7.3 Phase II 439

7.7.4 Phase I 486

7.7.5 Preclinical 543

7.7.6 Suspended 565

7.7.7 Ceased 566

7.8 The Competition Through Close Mechanistic Approximation of Lymphoma Drugs 591

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy 597

8.1 Small Molecules 599

8.1.1 Background 599

8.1.2 Target Strategies of Small Molecule Drugs 600

8.2 Peptide & Protein Drugs 610

8.2.1 Background 610

8.2.2 Target Strategies of Peptide and Protein Drugs 611

8.3 Antibodies 616

8.3.1 Background 616

8.3.2 Target Strategies of Antibody Drugs 616

8.4 Nucleic Acid Therapies 622

8.4.1 Background 622

8.4.2 Target Strategies of Nucleic Acid Drugs 623

8.5 Cell & Gene Therapy 625

8.5.1 Background 625

8.5.2 Target Strategies of Cell and Gene Therapy Drugs 626

8.6 Drug Delivery and Nanotechnology 629

8.6.1 Background 629

8.6.2 Target Strategies of Reformulated Drugs 629

8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 631

9 Selecting Subindication for Lymphoma Drugs 637

9.1 B-cell Lymphoma 638

9.2 Hodgkin's Lymphoma 641

9.3 non-Hodgkin's Lymphoma 644

9.4 T-cell Lymphoma 652

9.5 Lymphoma (general) 654

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator 658

10.1 Competitive Fall-Out Assessment 658

10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 660

10.3 4SC 661

10.4 Abbott 662

10.5 Abiogen 664

10.6 Advaxis 666

10.7 AEgera 667

10.8 AEterna Zentaris 669

10.9 Affimed Therapeutics 670

10.10 Agenus 672

10.11 Aida Pharmaceuticals 674

10.12 Alfa Wassermann 675

10.13 Alfacell 676

10.14 Allos Therapeutics 678

10.15 Ambit Biosciences 680

10.16 Amgen 681

10.17 Apricus Biosciences 684

10.18 Ariad 686

10.19 Arno Therapeutics 688

10.20 Ascenta Therapeutics 689

10.21 Astellas 691

10.22 Astex Therapeutics 694

10.23 AstraZeneca 695

10.24 Attenuon 698

10.25 AVEO 699

10.26 Bayer 700

10.27 Benitec 701

10.28 Biocon 702

10.29 BioCryst Pharmaceuticals 703

10.30 Biogen Idec 704

10.31 Biolex 709

10.32 Boehringer Ingelheim 711

10.33 Borean Pharma 712

10.34 Bristol-Myers Squibb 714

10.35 BTG 721

10.36 Celera 724

10.37 Celgene 726

10.38 Cell Therapeutics 729

10.39 Celldex Therapeutics 731

10.40 Celltrion 733

10.41 Cephalon 735

10.42 Cornerstone Pharmaceuticals 739

10.43 CureTech 740

10.44 Curis 741

10.45 Cyclacel 742

10.46 Cylene Pharmaceuticals 743

10.47 CytImmune Sciences 745

10.48 Cytokinetics 746

10.49 Daiichi Sankyo 748

10.50 Dainippon Sumitomo Pharma 750

10.51 Dara Biosciences 752

10.52 Dendreon 753

10.53 Dr Reddy's 754

10.54 Dynavax Technologies 756

10.55 Eisai 757

10.56 Eleos 759

10.57 Eli Lilly 760

10.58 Emergent BioSolutions 764

10.59 Enzon 767

10.60 EpiCept 768

10.61 Epizyme 769

10.62 Exelixis 770

10.63 Favrille 774

10.64 Forma Therapeutics 776

10.65 Gemin X Biotechnologies 777

10.66 Genencor 778

10.67 Genentech 779

10.68 Genmab 781

10.69 GenPat77 784

10.70 Genta 785

10.71 Genzyme 786

10.72 Gilead Sciences 788

10.73 GlaxoSmithKline 790

10.74 Hayashibara 796

10.75 Heber Biotec 797

10.76 HemaQuest 798

10.77 Hoffmann-La Roche 799

10.78 Human Genome Sciences 805

10.79 Hy BioPharma 807

10.80 IGF Oncology 808

10.81 ImmunoGen 809

10.82 Immunomedics 810

10.83 Inex 814

10.84 Innate Pharma 815

10.85 InNexus Biotechnology 817

10.86 Inovio 820

10.87 Intas Biopharmaceuticals 821

10.88 Intracel 822

10.89 Italfarmaco 824

10.90 Johnson & Johnson 825

10.91 Kinex 827

10.92 Kissei 828

10.93 Kyowa Hakko Kirin 830

10.94 Leo 833

10.95 LG Life Sciences 834

10.96 Ligand 836

10.97 Lorus Therapeutics 838

10.98 MacroGenics 840

10.99 Meda 841

10.100 MedImmune 843

10.101 Merck & Co 844

10.102 Merck KGaA 846

10.103 MethylGene 848

10.104 Micromet 850

10.105 Nektar Therapeutics 852

10.106 Nereus Pharmaceuticals 853

10.107 Nerviano Medical Sciences 854

10.108 NIH – The US National Institute of Health 855

10.109 Non-industrial Sources 856

10.110 Novartis 858

10.111 Noxxon 863

10.112 Nycomed Pharma 864

10.113 Onconova 866

10.114 Oncothyreon 868

10.115 Otsuka 869

10.116 Pfizer 870

10.117 Pharmacyclics 876

10.118 PharmaMar 878

10.119 Philogen 880

10.120 Piramal 881

10.121 Plexxikon 883

10.122 Portola Pharmaceuticals 884

10.123 ProNAi Therapeutics 886

10.124 Reata Pharmaceuticals 887

10.125 Regeneron 888

10.126 Reliance Life Sciences 889

10.127 Rigel 890

10.128 Sanofi-Aventis 892

10.129 Santaris Pharma 895

10.130 SBIO 897

10.131 Seattle Genetics 898

10.132 Selvita 901

10.133 Semafore Pharmaceuticals 902

10.134 Shire 903

10.135 SuperGen 904

10.136 SuppreMol 906

10.137 Synageva BioPharma 907

10.138 Takeda 909

10.139 Tapestry Pharmaceuticals 912

10.140 Tekmira Pharmaceuticals 914

10.141 Telik 915

10.142 TetraLogic Pharmaceuticals 916

10.143 Teva 917

10.144 Titan Pharmaceuticals 919

10.145 TopoTarget 920

10.146 Transgene 922

10.147 Trion Pharma 923

10.148 Vaccinex 925

10.149 VentiRx Pharmaceuticals 927

10.150 Vertex Pharmaceuticals 928

10.151 Vion Pharmaceuticals 929

10.152 XBiotech 931

10.153 Xencor 932

10.154 Yakult Honsha 934

10.155 Zenotech 935

10.156 Zenyaku Kogyo 937

11 Disclaimer 939

12 Drug Index 940

13 Company Index 948

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Lymphoma Drugs 329

Figure 2: The Drug-Target Competitive Landscape of Lymphoma Drugs - Large Clusters 331

Figure 3: The Drug-Target Competitive Landscape Lymphoma Drugs - Smaller Clusters 332

Figure 4: Head-to-Head Targeting Competitive Landscape of Lymphoma Drugs 333

Figure 5: Distribution of Compound Strategies among Lymphoma Drugs 631

Figure 6: Primary Sub-cellular Localization of Drug Targets 632

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7

Table 2: Breakdown of the Included Lymphoma Drug Pipeline by Stage of Development 26

Table 3: Head to Head Target Competition among Lymphoma Drugs 26

Table 4: Overview of Drug Target Strategy Themes 31

Table 5: Terminally Ceased Targets of Lymphoma Drugs 32

Table 6: Official Gene Name to Target Profle 32

Table 7: Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 316

Table 8: Identity of Lymphoma Drug Targets with Available Biological Structures 321

Table 9: Number of Target-Target Interactions among Targets of Lymphoma Drugs 325

Table 10: Available Protein Expression Profiles of Lymphoma Drugs Targets 334

Table 11: Pathway Summary 340

Table 12: Drug Targets without any Identified Assigned Pathways 340

Table 13: Pathway Profiles According to BioCarta of Lymphoma Drug Targets 342

Table 14: Pathway Profiles According to KEGG of Lymphoma Drug Targets 361

Table 15: Pathway Profiles According to NetPath of Lymphoma Drug Targets 383

Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 388

Table 17: Top Competitive Target Strategies of Lymphoma Drugs 389

Table 18: New and Unique Target Strategies of Pre-registration and Marketed Lymphoma Drugs 392

Table 19: The Competition Through Close Mechanistic Approximation Between Lymphoma Drugs being Marketed or in Pre-registration 393

Table 20: New and Unique Target Strategies in Phase III Clinical Development of Lymphoma Drugs 394

Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Lymphoma Drugs 394

Table 22: New and Unique Target Strategies in Phase II Clinical Development of Lymphoma Drugs 396

Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs 398

Table 24: New and Unique Target Strategies in Phase I Clinical Development of Lymphoma Drugs 400

Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs 403

Table 26: New and Unique Target Strategies in Preclinical Development of Lymphoma Drugs 405

Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Lymphoma Drugs 406

Table 28: Target Strategies of Suspended and Terminated Lymphoma Drugs 408

Table 29: Connecting Target Strategy with Its Profile Identification Number 410

Table 30: The Competition Through Close Mechanistic Approximation Among Lymphoma Drugs 591

Table 31: Overview of Compound Strategy Competition Among Lymphoma Drugs 598

Table 32: Overview of the Competitive Landscape of Small Molecule Based Lymphoma Drugs 600

Table 33: Competitive Comparison of Target Strategies of Small Molecule Lymphoma Drugs 601

Table 34: Pursued Target Strategies of Small Molecule Drugs Based Lymphoma Drugs 604

Table 35: Overview of the Competitive Landscape of Peptide Based Lymphoma Drugs 611

Table 36: Pursued Target Strategies of Peptide Based Lymphoma Drugs 612

Table 37: Overview of the Competitive Landscape of Protein Based Lymphoma Drugs 613

Table 38: Competitive Comparison of Target Strategies of Protein Based Lymphoma Drugs 614

Table 39: Pursued Target Strategies of Protein Based Lymphoma Drugs 614

Table 40: Overview of the Competitive Landscape of Antibody Based Lymphoma Drugs 616

Table 41: Competitive Comparison of Target Strategies of Antibody Based Lymphoma Drugs 617

Table 42: Pursued Target Strategies of Antibody Based Lymphoma Drugs 619

Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Lymphoma Drugs 623

Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Lymphoma Drugs 624

Table 45: Pursued Target Strategies of Nucleic Acid Based Lymphoma Drugs 624

Table 46: Potential Forms of Cell Therapy 625

Table 47: Vectors in Gene Therapy 626

Table 48: Overview of the Competitive Landscape of Cell Therapy Based Lymphoma Drugs 626

Table 49: Pursued Target Strategies of Cell Therapy Based Lymphoma Drugs 626

Table 50: Overview of the Competitive Landscape of Gene Therapy Based Lymphoma Drugs 627

Table 51: Pursued Target Strategies of Gene Therapy Based Lymphoma Drugs 628

Table 52:Overview of the Competitive Landscape of Reformulated Lymphoma Drugs 629

Table 53: Competitive Comparison of Target Strategies of Reformulated Lymphoma Drugs 630

Table 54: Pursued Target Strategies of Reformulated Lymphoma Drugs 630

Table 55: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets 632

Table 56 Competitive Summary by Subindication of Lymphoma Drugs 637

Table 57: Target Strategy Development Profiles of Drugs for the Treatment of B-cell Lymphoma Drugs 638

Table 58: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 640

Table 59: Target Strategy Development Profiles of Drugs for the Treatment of Hodgkin's Lymphoma 641

Table 60: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs 643

Table 61: Target Strategy Development Profiles of Drugs for the Treatment of non-Hodgkin's Lymphoma 644

Table 62: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 649

Table 63: Target Strategy Development Profiles of Drugs for the Treatment of T-cell Lymphoma 652

Table 64: The Competition through Close Mechanistic Approximation between T-cell Lymphoma Drugs 653

Table 65: Target Strategy Development Profiles of Drugs for the Treatment of Lymphoma (general) 654

Table 66: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs 657

Table 67: Example of a Competitive Fall-Out Table (Targeting MS4A1) 659

Table 68: Summary Table of Corporate Changes in the Competitive Landscape of Lymphoma Drug Development 660

Table 69: 4SC's Included Lymphoma Pipeline and Competitive Fall-Out 661

Table 70: Abbott's Included Lymphoma Pipeline and Competitive Fall-Out 662

Table 71: Abiogen's Included Lymphoma Pipeline and Competitive Fall-Out 664

Table 72: Advaxis' Included Lymphoma Pipeline and Competitive Fall-Out 666

Table 73: AEgera's Included Lymphoma Pipeline and Competitive Fall-Out 667

Table 74: AEterna Zentaris' Included Lymphoma Pipeline and Competitive Fall-Out 669

Table 75: Affimed Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 670

Table 76: Agenus' Included Lymphoma Pipeline and Competitive Fall-Out 672

Table 77: Aida Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 674

Table 78: Alfa Wassermann's Included Lymphoma Pipeline and Competitive Fall-Out 675

Table 79: Alfacell's Included Lymphoma Pipeline and Competitive Fall-Out 676

Table 80: Allos Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 678

Table 81: Ambit Biosciences' Included Lymphoma Pipeline and Competitive Fall-Out 680

Table 82: Amgen's Included Lymphoma Pipeline and Competitive Fall-Out 681

Table 83: Apricus Biosciences' Included Lymphoma Pipeline and Competitive Fall-Out 684

Table 84: Ariad's Included Lymphoma Pipeline and Competitive Fall-Out 686

Table 85: Arno Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 688

Table 86: Ascenta Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 689

Table 87: Astellas' Included Lymphoma Pipeline and Competitive Fall-Out 691

Table 88: Astex Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 694

Table 89: AstraZeneca's Included Lymphoma Pipeline and Competitive Fall-Out 695

Table 90: Attenuon's Included Lymphoma Pipeline and Competitive Fall-Out 698

Table 91: AVEO's Included Lymphoma Pipeline and Competitive Fall-Out 699

Table 92: Bayer's Included Lymphoma Pipeline and Competitive Fall-Out 700

Table 93: Benitec's Included Lymphoma Pipeline and Competitive Fall-Out 701

Table 94: Biocon's Included Lymphoma Pipeline and Competitive Fall-Out 702

Table 95: BioCryst Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 703

Table 96: Biogen Idec's Included Lymphoma Pipeline and Competitive Fall-Out 704

Table 97: Biolex's Included Lymphoma Pipeline and Competitive Fall-Out 709

Table 98: Boehringer Ingelheim's Included Lymphoma Pipeline and Competitive Fall-Out 711

Table 99: Borean Pharma's Included Lymphoma Pipeline and Competitive Fall-Out 712

Table 100: Bristol-Myers Squibb's Included Lymphoma Pipeline and Competitive Fall-Out 714

Table 101: BTG's Included Lymphoma Pipeline and Competitive Fall-Out 721

Table 102: Celera's Included Lymphoma Pipeline and Competitive Fall-Out 724

Table 103: Celgene's Included Lymphoma Pipeline and Competitive Fall-Out 726

Table 104: Cell Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 729

Table 105: Celldex Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 731

Table 106: Celltrion's Included Lymphoma Pipeline and Competitive Fall-Out 733

Table 107: Cephalon's Included Lymphoma Pipeline and Competitive Fall-Out 735

Table 108: Cornerstone Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 739

Table 109: CureTech's Included Lymphoma Pipeline and Competitive Fall-Out 740

Table 110: Curis' Included Lymphoma Pipeline and Competitive Fall-Out 741

Table 111: Cyclacel's Included Lymphoma Pipeline and Competitive Fall-Out 742

Table 112: Cylene Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 743

Table 113: CytImmune Sciences' Included Lymphoma Pipeline and Competitive Fall-Out 745

Table 114: Cytokinetics' Included Lymphoma Pipeline and Competitive Fall-Out 746

Table 115: Daiichi Sankyo's Included Lymphoma Pipeline and Competitive Fall-Out 748

Table 116: Dainippon Sumitomo Pharma's Included Lymphoma Pipeline and Competitive Fall-Out 750

Table 117: Dara Biosciences' Included Lymphoma Pipeline and Competitive Fall-Out 752

Table 118: Dendreon's Included Lymphoma Pipeline and Competitive Fall-Out 753

Table 119: Dr Reddy's' Included Lymphoma Pipeline and Competitive Fall-Out 754

Table 120: Dynavax Technologies' Included Lymphoma Pipeline and Competitive Fall-Out 756

Table 121: Eisai's Included Lymphoma Pipeline and Competitive Fall-Out 757

Table 122: Eleos' Included Lymphoma Pipeline and Competitive Fall-Out 759

Table 123: Eli Lilly's Included Lymphoma Pipeline and Competitive Fall-Out 760

Table 124: Emergent BioSolutions' Included Lymphoma Pipeline and Competitive Fall-Out 764

Table 125: Enzon's Included Lymphoma Pipeline and Competitive Fall-Out 767

Table 126: EpiCept's Included Lymphoma Pipeline and Competitive Fall-Out 768

Table 127: Epizyme's Included Lymphoma Pipeline and Competitive Fall-Out 769

Table 128: Exelixis' Included Lymphoma Pipeline and Competitive Fall-Out 770

Table 129: Favrille's Included Lymphoma Pipeline and Competitive Fall-Out 774

Table 130: Forma Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 776

Table 131: Gemin X Biotechnologies' Included Lymphoma Pipeline and Competitive Fall-Out 777

Table 132: Genencor's Included Lymphoma Pipeline and Competitive Fall-Out 778

Table 133: Genentech's Included Lymphoma Pipeline and Competitive Fall-Out 779

Table 134: Genmab's Included Lymphoma Pipeline and Competitive Fall-Out 781

Table 135: GenPat77's Included Lymphoma Pipeline and Competitive Fall-Out 784

Table 136: Genta's Included Lymphoma Pipeline and Competitive Fall-Out 785

Table 137: Genzyme's Included Lymphoma Pipeline and Competitive Fall-Out 786

Table 138: Gilead Sciences' Included Lymphoma Pipeline and Competitive Fall-Out 788

Table 139: GlaxoSmithKline's Included Lymphoma Pipeline and Competitive Fall-Out 790

Table 140: Hayashibara's Included Lymphoma Pipeline and Competitive Fall-Out 796

Table 141: Heber Biotec's Included Lymphoma Pipeline and Competitive Fall-Out 797

Table 142: HemaQuest's Included Lymphoma Pipeline and Competitive Fall-Out 798

Table 143: Hoffmann-La Roche's Included Lymphoma Pipeline and Competitive Fall-Out 799

Table 144: Human Genome Sciences' Included Lymphoma Pipeline and Competitive Fall-Out 805

Table 145: Hy BioPharma's Included Lymphoma Pipeline and Competitive Fall-Out 807

Table 146: IGF Oncology's Included Lymphoma Pipeline and Competitive Fall-Out 808

Table 147: ImmunoGen's Included Lymphoma Pipeline and Competitive Fall-Out 809

Table 148: Immunomedics' Included Lymphoma Pipeline and Competitive Fall-Out 810

Table 149: Inex's Included Lymphoma Pipeline and Competitive Fall-Out 814

Table 150: Innate Pharma's Included Lymphoma Pipeline and Competitive Fall-Out 815

Table 151: InNexus Biotechnology's Included Lymphoma Pipeline and Competitive Fall-Out 817

Table 152: Inovio's Included Lymphoma Pipeline and Competitive Fall-Out 820

Table 153: Intas Biopharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 821

Table 154: Intracel's Included Lymphoma Pipeline and Competitive Fall-Out 822

Table 155: Italfarmaco's Included Lymphoma Pipeline and Competitive Fall-Out 824

Table 156: Johnson & Johnson's Included Lymphoma Pipeline and Competitive Fall-Out 825

Table 157: Kinex's Included Lymphoma Pipeline and Competitive Fall-Out 827

Table 158: Kissei's Included Lymphoma Pipeline and Competitive Fall-Out 828

Table 159: Kyowa Hakko Kirin's Included Lymphoma Pipeline and Competitive Fall-Out 830

Table 160: Leo's Included Lymphoma Pipeline and Competitive Fall-Out 833

Table 161: LG Life Sciences' Included Lymphoma Pipeline and Competitive Fall-Out 834

Table 162: Ligand's Included Lymphoma Pipeline and Competitive Fall-Out 836

Table 163: Lorus Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 838

Table 164: MacroGenics' Included Lymphoma Pipeline and Competitive Fall-Out 840

Table 165: Meda's Included Lymphoma Pipeline and Competitive Fall-Out 841

Table 166: MedImmune's Included Lymphoma Pipeline and Competitive Fall-Out 843

Table 167: Merck & Co's Included Lymphoma Pipeline and Competitive Fall-Out 844

Table 168: Merck KGaA's Included Lymphoma Pipeline and Competitive Fall-Out 846

Table 169: MethylGene's Included Lymphoma Pipeline and Competitive Fall-Out 848

Table 170: Micromet's Included Lymphoma Pipeline and Competitive Fall-Out 850

Table 171: Nektar Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 852

Table 172: Nereus Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 853

Table 173: Nerviano Medical Sciences' Included Lymphoma Pipeline and Competitive Fall-Out 854

Table 174: NIH's Included Lymphoma Pipeline and Competitive Fall-Out 855

Table 175: Non-industrial Source's Included Lymphoma Pipeline and Competitive Fall-Out 856

Table 176: Novartis' Included Lymphoma Pipeline and Competitive Fall-Out 858

Table 177: Noxxon's Included Lymphoma Pipeline and Competitive Fall-Out 863

Table 178: Nycomed Pharma's Included Lymphoma Pipeline and Competitive Fall-Out 864

Table 179: Onconova's Included Lymphoma Pipeline and Competitive Fall-Out 866

Table 180: Oncothyreon's Included Lymphoma Pipeline and Competitive Fall-Out 868

Table 181: Otsuka's Included Lymphoma Pipeline and Competitive Fall-Out 869

Table 182: Pfizer's Included Lymphoma Pipeline and Competitive Fall-Out 870

Table 183: Pharmacyclics' Included Lymphoma Pipeline and Competitive Fall-Out 876

Table 184: PharmaMar's Included Lymphoma Pipeline and Competitive Fall-Out 878

Table 185: Philogen's Included Lymphoma Pipeline and Competitive Fall-Out 880

Table 186: Piramal's Included Lymphoma Pipeline and Competitive Fall-Out 881

Table 187: Plexxikon's Included Lymphoma Pipeline and Competitive Fall-Out 883

Table 188: Portola Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 884

Table 189: ProNAi Therapeutics' Included Lymphoma Pipeline and Competitive Fall-Out 886

Table 190: Reata Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 887

Table 191: Regeneron's Included Lymphoma Pipeline and Competitive Fall-Out 888

Table 192: Reliance Life Sciences' Included Lymphoma Pipeline and Competitive Fall-Out 889

Table 193: Rigel's Included Lymphoma Pipeline and Competitive Fall-Out 890

Table 194: Sanofi-Aventis' Included Lymphoma Pipeline and Competitive Fall-Out 892

Table 195: Santaris Pharma's Included Lymphoma Pipeline and Competitive Fall-Out 895

Table 196: SBIO's Included Lymphoma Pipeline and Competitive Fall-Out 897

Table 197: Seattle Genetics' Included Lymphoma Pipeline and Competitive Fall-Out 898

Table 198: Selvita's Included Lymphoma Pipeline and Competitive Fall-Out 901

Table 199: Semafore Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 902

Table 200: Shire's Included Lymphoma Pipeline and Competitive Fall-Out 903

Table 201: SuperGen's Included Lymphoma Pipeline and Competitive Fall-Out 904

Table 202: SuppreMol's Included Lymphoma Pipeline and Competitive Fall-Out 906

Table 203: Synageva BioPharma's Included Lymphoma Pipeline and Competitive Fall-Out 907

Table 204: Takeda's Included Lymphoma Pipeline and Competitive Fall-Out 909

Table 205: Tapestry Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 912

Table 206: Tekmira Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 914

Table 207: Telik's Included Lymphoma Pipeline and Competitive Fall-Out 915

Table 208: TetraLogic Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 916

Table 209: Teva's Included Lymphoma Pipeline and Competitive Fall-Out 917

Table 210: Titan Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 919

Table 211: TopoTarget's Included Lymphoma Pipeline and Competitive Fall-Out 920

Table 212: Transgene's Included Lymphoma Pipeline and Competitive Fall-Out 922

Table 213: Trion Pharma's Included Lymphoma Pipeline and Competitive Fall-Out 923

Table 214: Vaccinex's Included Lymphoma Pipeline and Competitive Fall-Out 925

Table 215: VentiRx Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 927

Table 216: Vertex Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 928

Table 217: Vion Pharmaceuticals' Included Lymphoma Pipeline and Competitive Fall-Out 929

Table 218: XBiotech's Included Lymphoma Pipeline and Competitive Fall-Out 931

Table 219: Xencor's Included Lymphoma Pipeline and Competitive Fall-Out 932

Table 220: Yakult Honsha's Included Lymphoma Pipeline and Competitive Fall-Out 934

Table 221: Zenotech's Included Lymphoma Pipeline and Competitive Fall-Out 935

Table 222: Zenyaku Kogyo's Included Lymphoma Pipeline and Competitive Fall-Out 937

To order this report:

Pathology Industry: A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Orphan Drugs in Asia 2011
2. Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry
3. Reportlinker Adds The Outlook for Medical Devices in South East Asia
4. Reportlinker Adds Pharmaceutical Management of Obesity (Technical Insights)
5. Reportlinker Adds Machine-to-Machine (M2M) Communications in Healthcare 2010-20
6. Reportlinker Adds Hong Kong SMBG Devices and Strips Market
7. Reportlinker Adds Medical Devices Reports Bundle
8. Reportlinker Adds Impact of Healthcare Reforms on the Medical Technology Industry
9. Reportlinker Adds Pharmaceuticals Reports Bundle
10. Reportlinker Adds North America Hospital Supplies Market Outlook to 2017
11. Reportlinker Adds Asia Pacific Hospital Supplies Market Outlook to 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Mettler-Toledo International Inc. (NYSE: MTD ) today ... the highlights: , Sales in local currency ... year.  Reported sales decreased 3% as currency reduced sales ... earnings per diluted share as reported (EPS) were $4.44, ... EPS was $4.65, an increase of 10% over the ...
(Date:2/4/2016)... -- In response to the opioid abuse epidemic, today Dr. ... Products and Tobacco, along with other FDA leaders, called for ... opioid medications. The plan will focus on policies aimed at ... to effective relief. --> ... risk-benefit paradigm for opioids and ensure that the agency considers ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality President ... next generation LYNX VR Indoor Trainer with multi-rider capability to an enthusiastic audience ... not only reduce the weight of the unit, they also enhance the rider's ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and Heather ... Napa Valley office. The technique utilizes the body’s own healing abilities to quickly ... Furnas, are part of only a select few cosmetic surgeons bringing this procedure ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
(Date:2/5/2016)... ... ... Boar’s Head Brand®, one of the nation’s leading providers of premium delicatessen foods, ... out of your party preparation – follow these easy, yet delicious recipes with the ... , “The key to hosting a successful game-day party is creating a flavorful menu ...
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
Breaking Medicine News(10 mins):